Senate panel rejects Trump budget health cuts
The bill includes a $100 million increase for Alzheimer's disease research, a $150 million increase for cancer research and a $30 million increase for the Office of Research on Women's Health.
While funding for other parts of the Department of Health and Human Services (HHS) was left the same, it was still a far cry from the major cuts put forward by the White House.
'To the scientists wondering if there will even be an NIH by the end of this administration: this committee's resounding message is yes,' said Sen. Patty Murray (D-Wash.), the committee's vice chair.
The panel also did not include a massive HHS reorganization that would have created a new Administration for a Healthy America (AHA) to focus on chronic disease prevention.
The White House budget request called for the new AHA agency to absorb other existing agencies and programs within the Centers for Disease Control and Prevention, as well as the entire Substance Abuse and Mental Health Services Administration, the Health Resources and Services Administration, the Office of the Assistant Secretary for Health, and the National Institute of Environmental Health Sciences.
The administration proposed giving the AHA agency a budget of $20 billion. But lawmakers on Thursday never mentioned it.
An Appropriations Committee spokesperson told The Hill that HHS never sent Congress the required formal reorganization plan or allow for six months of consideration.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
This tasty seasoning can boost memory, fight anxiety and even help prevent dementia
Herb your enthusiasm — your brain's about to get a boost. For centuries, a trusty kitchen staple has been celebrated by ancient healers for its wide-ranging medicinal properties, including sharpening memory, concentration and overall cognitive function. Now, modern science is backing up that old-school wisdom, with research suggesting the powerful plant could even help fight Alzheimer's disease, the leading cause of dementia worldwide. Advertisement 5 The herb is generally considered safe for culinary and medicinal purposes when used in moderation. rh2010 – A Mediterranean marvel Rosemary, a fragrant evergreen shrub native to the Mediterranean, has been a kitchen staple since the time of ancient Greece and Rome. Fast forward to today, and the versatile herb has won fans around the world. Its bold, aromatic leaves — whether fresh or dried — are widely used as seasoning, steeped in tea or infused into oil. Advertisement But could adding rosemary to your meals do more than just wake up your taste buds? More than just flavor Packed with phytochemicals, rosemary has been shown to help protect the body from harmful free radicals, oxidative stress and inflammation — all key drivers behind chronic illnesses like cancer, heart disease and type 2 diabetes. 5 Rosemary is part of the mint family, which also includes herbs like basil, thyme and lavender. PhotoArt Thomas Klee – It also appears to pack an antimicrobial punch, having long been used in traditional medicine to fight infections and speed wound healing. Advertisement Rosemary is a solid source of vitamins A, C and B6, along with essential minerals like iron, calcium, magnesium and potassium. It's especially rich in manganese, a key nutrient for metabolic health. With all these benefits, scientists are investigating whether rosemary could help with everything from vision and skin health to hair growth, asthma relief and even slowing the spread of cancer cells. But one of the most promising frontiers in rosemary research is the brain. Brain food since ancient times Advertisement Scientists may be just catching on, but humans have relied on rosemary to boost brainpower for thousands of years. 5 Rosemary's potent tioxidant and anti-inflammatory properties may give the brain a major boost. manassanant – Back in ancient Greece, students and scholars commonly wore garlands made from the plant on their heads during exams to boost their memory and focus. Centuries later, Shakespeare crowned it 'the herb of remembrance.' Turns out, they might have been onto something. In one study, older adults who sniffed rosemary scored significantly better on tests of prospective memory — the ability to remember to do something at the right time — compared to those in an unscented room. They were also more alert. 'This is potentially very important because prospective memory, for example, enables you to remember to take your medication at certain times of the day,' said Dr. Mark Moss, head of the department of psychology at Northumbria University, who helped lead the study. 5 The scent of rosemary has been shown to improve memory and focus, as well as lower stress and anxiety levels. annanahabed – Advertisement But it's not just seniors who could benefit. A 2018 trial found university students taking 500 mg of rosemary supplements twice daily for a month showed better memory than a placebo group. They also reported less anxiety and depression, plus better sleep — suggesting rosemary does more than just sharpen your mind. In another study, employees who drank rosemary-infused water daily said they felt less burnt out at their jobs than coworkers who didn't. Advertisement Scientists think rosemary may work its magic by boosting blood flow to the brain — flooding it with oxygen and nutrients that help clear out mental fog. Its calming scent has also been shown to lower cortisol, the body's main stress hormone. Meanwhile, research suggests its polyphenols may help fight depression by taming inflammation and supporting gut health. Rosemary also contains compounds like 1,8-cineole, which helps prevent the breakdown of acetylcholine — a key brain chemical tied to learning and memory. Experts suspect that keeping acetylcholine levels up may help your mind stay sharp with age. Advertisement 5 Over time, Alzheimer's disease gradually destroys thinking and memory skills. LIGHTFIELD STUDIOS – Researchers are also zeroing in on carnosic acid, a powerful antioxidant in rosemary that shields brain cells from damage linked to Alzheimer's disease. In 2025, researchers created a stable version called diAcCA, and early lab results are promising. The compound improved memory, strengthened brain cell connections and slashed levels of Alzheimer's-linked proteins like amyloid-beta and tau. Even better, diAcCA only activated in inflamed brain areas, potentially reducing side effects. In mouse studies, it showed no signs of toxicity and delivered major cognitive gains — raising hopes for future human trials. Advertisement The breakthrough could be big, with Alzheimer's becoming a growing public health crisis as America's population gets older. Right now, about 7.2 million Americans over 65 have the memory-robbing disease. By 2060, that number is expected to nearly double to 13.8 million unless new treatments or cures emerge.
Yahoo
an hour ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
2 hours ago
- Newsweek
California Hits Back at Trump's $200M UCLA Grant Freeze: 'Manipulation'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. California's Governor Gavin Newsom has condemned the Trump administration's suspension of research grants for the University of California, Los Angeles (UCLA), over alleged antisemitism. The U.S. Department of Justice froze hundreds of millions of dollars in medical and science research grants to UCLA over allegations of campus antisemitism and use of race in admissions. "It is a cruel manipulation to use Jewish students' real concerns about antisemitism on campus as an excuse to cut millions of dollars in grants," Newsom said in a statement. Newsweek has contacted the Justice Department for comment. File photo: Gavin Newsom looks on at Downey Memorial Christian Church in Downey, California, on July 16, 2025. File photo: Gavin Newsom looks on at Downey Memorial Christian Church in Downey, California, on July 16, 2025. Patrick T. Fallon/Getty Images Why It Matters Newsom's comments fuel his confrontation with the Trump administration, the latter seeking to put pressure on universities after student protests on college campuses about the war in Gaza were dubbed antisemitic by some lawmakers and groups. What To Know The U.S. Department of Justice said this week that the UCLA had violated the civil rights of Jewish students during pro-Palestinian protests. The university's Chancellor Julio Frenk said he was told that the federal government, through its control of the National Science Foundation (NSF), the National Institutes of Health (NIH) and other agencies, was suspending certain research funding to the UCLA. The Department of Health and Human Services, of which NIH is a part, said in a statement that it would "not fund institutions that promote antisemitism." The UCLA had earlier announced it had agreed a $6 million settlement of alleged discrimination brought by Jewish students and a faculty member. The lawsuit accused the university of failing to take action when pro-Palestinian protesters set up encampments on campus in spring 2024. The Los Angeles Times said university leaders had been expecting this moment for months amid federal investigations into alleged use of race in admissions, employment discrimination against Jews, and civil-rights complaints from Jewish students. But Frenk said Thursday that the pausing of funding—whose amount he did not reveal but which Newsom said was around $200 million—was a loss to both researchers and Americans whose health benefits from its work. The LA Times reported that the amount was $300 million. Frenk said that antisemitism "has no place on our campus, nor does any form of discrimination," adding that "we recognize that we can improve." Newsom weighed in with a statement Friday that said that freezing the funding—which would investigate invasive diseases, "cure cancer, and build new defense technologies—makes our country less safe." What People Are Saying California Governor Gavin Newsom said: "Freezing critical research funding for UCLA—dollars that were going to study invasive diseases, cure cancer, and build new defense technologies—makes our country less safe." UCLA Chancellor Julio Frenk said in a statement on the freezing of funding: "[It] is not only a loss to the researchers who rely on critical grants. It is a loss for Americans across the nation whose work, health, and future depend on the groundbreaking work we do." What Happens Next The LA Times reported that it is not clear what steps the UCLA might take, but Newsom has said he was "reviewing" the Justice Department's findings.
